{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Intensity of an AE is defined as:', 'Mild: no modification of daily activities and does not require mandatory', 'corrective/symptomatic treatment.', 'Moderate: hinders normal daily activities and/or requires mandatory', 'corrective/symptomatic treatment.', 'Severe: prevents daily activities and requires mandatory corrective/symptomatic treatment.', '10.4.1.2 Serious adverse event', 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose:', 'Results in death, or,', 'Is life-threatening, or,', 'Note: The term \"life-threatening\" in the definition of \"serious\" refers to an event in which', 'the patient was at risk of death at the time of the event; it does not refer to an event which', 'hypothetically might have caused death if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization, or,', 'Results in persistent or significant disability/incapacity, or,', 'Is a congenital anomaly/birth defect.', 'Is a medically important event.', 'Medical and scientific judgment should be exercised in deciding whether expedited', 'reporting is appropriate in other situations, such as important medical events that may not', 'be immediately life-threatening or result in death or hospitalization but may jeopardize the', 'patient or may require medical or surgical intervention (ie, specific measures or corrective', 'treatment) to prevent one of the other outcomes listed in the definition above.', 'Note: The following list of medically important events is intended to serve as a guideline for', 'determining which condition has to be considered a medically important event. The list is not', 'intended to be exhaustive:', 'Intensive treatment in an emergency room or at home for:', '-', 'Allergic bronchospasm,', '-', 'Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia,', 'myelodysplasia, pancytopenia, etc),', '-', 'Convulsions (seizures, epilepsy, epileptic fit, absence, etc).', 'ALT >3 X ULN + total bilirubin >2 X ULN or asymptomatic ALT increase >5 X ULN.', 'Syncope, loss of consciousness (except if documented as a consequence of blood', 'sampling).', 'Bullous cutaneous eruptions.', 'Property of the Sanofi Group - strictly confidential', 'Page 71', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '10.4.1.3 Adverse event of special interest', 'An adverse event of special interest (AESI) is an AE (serious or nonserious) of scientific and', \"medical concern specific to the Sponsor's product or program, for which ongoing monitoring and\", 'immediate notification by the Investigator to the Sponsor is required. Such events may require', 'further investigation in order to characterize and understand them. Adverse events of special', 'interest may be added, modified or removed during a study by protocol amendment.', 'Pregnancy of a female subject entered in a study as well as pregnancy occurring in a', 'female partner of a male subject entered in a study with IMP:', '-', 'Pregnancy occurring in a female patient entered in the clinical trial or in a female', 'partner of a male patient entered in the clinical trial. It will be qualified as an SAE only', 'if it fulfills one of the seriousness criteria (see Section 10.4.1.2),', '-', 'In the event of pregnancy in a female participant, IMP should be discontinued,', '-', 'Follow-up of the pregnancy in a female participant or in a female partner of a male', 'participant is mandatory until the outcome has been determined.', 'Symptomatic overdose (serious or nonserious) with IMP:', '-', 'An overdose (accidental or intentional) with the IMP is an event suspected by the', 'Investigator or spontaneously notified by the patient (not based on systematic pills', 'count) and defined as at least twice the intended dose within the intended therapeutic', 'interval, adjusted according to the tested drug.', 'Of note, asymptomatic overdose has to be reported as a standard AE.', 'Increase in alanine transaminase (ALT)>3xULN (see Appendix A of the protocol).', 'QTc >500ms.', 'Hypotension/orthostatic hypotension symptomatic or not defined as:', '-', 'Asymptomatic orthostatic hypotension with SBP decrease at Minute 3 or Minute 5', 'between seated and standing position >30 mmHg,', '-', 'SBP <90 mmHg,', '-', 'Symptomatic orthostatic hypotension with SBP decrease at Minute 3 or Minute 5', 'between seated and standing position >20 mmHg,', '-', 'Symptoms of hypotension (either orthostatic or non-postural) include: presyncope,', 'including any symptoms of dizziness, faintness or lightheadedness appearing while', 'standing up and possibly caused by a drop in BP and/or appearing while standing up,', '-', 'Whenever possible, concomitant medications, BP and heart rate measurements in', 'seated and standing positions, plasma glucose level and ECG will be collected at or', \"near the time of the event or per the investigator's clinical judgment,\", '-', 'For any such event, the appropriate AESI eCRF screen must be filled out.', 'Note: the following non-pharmacological measures will be encouraged by discussing with the', 'patient: If a patient experiences faint-headedness or unusual dizziness, he or she will assume a', 'seated position and, if still dizzy, either lie down or, while seated, place the head between the', 'knees until dizziness has passed; the patient will be recommended to drink at least 12 ounces', '(375 mL) of fluid.', 'Property of the Sanofi Group - strictly confidential', 'Page 72', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}